OraSure Technologies, Inc. (OSUR) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: strong core revenue and gross margin improvements are positive, but significant challenges include revenue decline from a major customer, NIH funding cuts, and high operating losses. The Q&A reveals uncertainties in revenue guidance and manufacturing transition impacts. The share repurchase is a slight positive, but overall, the sentiment is neutral due to balanced positive and negative factors. The lack of clear guidance and uncertainties in key areas temper potential optimism.
Key Financial Performance
Core Revenue $30.8 million, above the midpoint of guidance range. Diagnostics grew 3% year-over-year, while Sample Management revenue decreased 22% year-over-year due to a large customer in the Consumer Genetics segment. Excluding this customer, Sample Management revenue growth would have been positive, and overall core revenue growth would have been 5% year-over-year.
Total Revenue $31.2 million. Core revenue was $30.8 million, with COVID-19 and risk assessment testing products contributing $474,000. Total revenue was influenced by the decline in revenue from the large consumer genetics customer.
Diagnostics Revenue $19.2 million, grew 3% year-over-year. Growth was achieved despite challenges in international markets due to USAID funding freezes and slower deployment of HIV tests.
Sample Management Solutions Revenue $9.9 million. Excluding the headwind from the consumer genetics customer, revenue from the rest of the customer base grew year-over-year.
Gross Margin GAAP gross margin was 42.1%, and non-GAAP gross margin was 43.2%, better than expectations.
Operating Loss GAAP operating loss was $18 million, and non-GAAP operating loss was $13.2 million.
Cash and Cash Equivalents $235 million at the end of Q2, with 0 debt. Operating cash flow was negative $10 million, consistent with expectations due to investments in innovation and clinical trials.
Share Repurchase $5 million deployed to repurchase 1.8 million shares of common stock during Q2.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
HEMAcollect PROTEIN: Launched in July to meet the needs of proteomic researchers. Expands Sample Management Solutions into blood samples, offering extended protein stabilization at room temperature and simplified workflows.
Colli-Pee device: Progressing towards a 2025 FDA submission. Designed for first void urine collection, targeting markets like STIs, HPV, and oncology. Offers non-invasive testing with high sensitivity and specificity.
Sherlock CT/NG test: Clinical study for an over-the-counter molecular self-test for chlamydia and gonorrhea is on track for FDA submission by the end of 2025. Aims to provide lab-like performance at an affordable price.
International HIV testing market: Despite disruptions due to USAID funding freezes, the company remains confident in its competitive positioning due to its unique oral fluid-based rapid test and strong customer relationships.
U.S. Diagnostics business: Revenue declined 1% year-over-year in the first half of 2025. Public health customers face budget uncertainties and staffing reductions.
Sample Management business: Commercial segment grew in the first half of 2025, excluding disruptions from a large consumer genetics customer. Renewed agreement with GeneDx and collaboration with targeted genomics for GlutenID.
Transition to in-house manufacturing: Substantially completed the transition from external contract manufacturing to internal capabilities in Pennsylvania, ahead of schedule. Expected to improve operational efficiencies in 2025 and 2026.
Leadership changes: Anne Messing joined as Chief Commercial Officer to drive market leadership and growth. Brings over 25 years of experience in life sciences and diagnostics.
Capital deployment: Repurchased 1.8 million shares for $5 million in Q2. Evaluating inorganic growth opportunities to expand the product portfolio and accelerate revenue.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Funding Uncertainty for Public Health Programs: Elevated levels of uncertainty related to funding for public health programs and research, impacting customer alignment and revenue stability.
USAID Funding Freezes: Disruption in international diagnostics business due to USAID funding freezes, slowing the pace of HIV test deployment in affected geographies.
Potential Budget Cuts for U.S. Public Health Agencies: Uncertainty around potential budget cuts and staffing reductions at HHS, CDC, and other agencies, affecting public health program operations.
Together Take Me Home Program Funding: Uncertainty regarding the continuation and funding levels of the Together Take Me Home program, which impacts revenue from HIV self-tests.
Consumer Genetics Customer Disruption: Significant revenue decline from a large consumer genetics customer, with no anticipated recovery in 2025.
NIH Funding Reductions: Negative impact on academic and research customers due to reductions in NIH funding, affecting Sample Management Solutions revenue.
Transition to In-House Manufacturing: Operational challenges and gradual ramp-up of efficiencies from transitioning Sample Management Solutions manufacturing to in-house capabilities.
Sherlock Platform Investments: High investment costs in the Sherlock platform and CT/NG clinical trial, contributing to operating losses.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for Q3 2025: The company is guiding to third quarter revenue of $27 million to $30 million, influenced by international order trends in the diagnostics business and the timing of orders from the Together Take Me Home program in the U.S. This guidance also assumes continued disruption in ordering patterns from the SMS customer in the consumer genetics industry.
Gross Margin Expectations: Gross margin percentage in Q3 is expected to be consistent with the second quarter.
Operating Efficiencies: Operating efficiencies from the transition to in-house manufacturing are expected to gradually ramp up in the second half of 2025 and gain additional momentum in 2026.
Operating Expenses for Q3 2025: Core operating expenses are expected to be approximately $20 million plus $10 million of investments in innovation, including $7 million to $8 million related to Sherlock.
Revenue Recovery in 2026: The company expects to return to growth in 2026 as end segments and customers adapt to the new normal environment.
Product Launches and Innovation: Investments in new products such as Colli-Pee urine collection and Sherlock low-cost molecular diagnostics are expected to deliver strong returns beginning in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: We deployed $5 million during the second quarter to repurchase 1.8 million shares of our common stock.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide specifics on the 3Q guidance, particularly regarding the HIV and HCV platforms, and the margin line with the transition to in-house manufacturing?
A:Kenneth J. McGrath explained that Q3 margins are expected to be consistent with Q2, with benefits from transitioning manufacturing in-house starting in the second half of the year and ramping up in 2026. Carrie Eglinton Manner added that while segment guidance isn't provided, the Together Take Me Home program's expected revenue is reduced to $0.5 million per quarter. For HCV, stability is expected quarter-over-quarter, while HIV international orders are slower due to USAID funding disruptions and inventory adjustments.
Q:What is the initial traction and feedback for the blood proteomics product, and what are the targeted areas and potential opportunities?
A:Carrie Eglinton Manner stated that the HEMAcollect PROTEIN launch has seen enthusiastic customer engagement. The product stabilizes proteins for up to 7 days at room temperature, aiding operational efficiency and analysis. Targeted areas include oncology, neurology, cardiology, and cardiometabolic disorders, with broad applications in clinical disease research. Momentum is expected to grow into 2026.
Q:Was there any impact from moving manufacturing back in-house on gross margins, and what were the contributing factors?
A:Kenneth J. McGrath noted that gross margin improvements were primarily due to manufacturing changes, including packaging and reagent internalization, which are volume-dependent. Lower scrap rates also contributed to the improvement in Q2.
Q:What drove the better-than-expected performance in Diagnostics, and were there any pull-forwards from tariffs?
A:Kenneth J. McGrath attributed the performance to timing benefits from international orders and the Together Take Me Home program. However, a slowdown is expected in Q3 due to inventory adjustments in Africa. Carrie Eglinton Manner added that efforts to expand into clinical healthcare settings and introduce the Syphilis Health Check alongside HIV and HCV offerings are offsetting public health challenges.
Q:Review of Unclear Management Responses
A:Management avoided providing specific segment guidance for Q3 revenue, instead offering general comments on the Together Take Me Home program and HIV/HCV dynamics. Additionally, funding details for the HIV program were not shared, and responses included uncertainty and potential outcomes without concrete data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CT NG
Chief Commercial
Colli Pee
Commercial Officer
GeneDx
GlutenID
HEMAcollect PROTEIN
Home
Messing
PROTEIN offering
SMS
Sherlock
Vice President
assessment testing
capability Pennsylvania
consumer genetics
deployment
disruption
funding
genetics customer
genomics
health program
life
map order
order portfolio
pace
product capability
risk assessment
risk gene
road map
sample collection
test home
test lab
testing market
transition
vision
OSUR Transcript
OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call indicates strong financial performance with a 10% YoY revenue increase and improved gross margins. Net income shifted from a loss to a profit, and cash flow from operations increased significantly. Despite potential risks highlighted in forward-looking statements, the financial health and positive outlook on product demand suggest a positive market reaction.
OraSure Technologies, Inc. (OSUR) Q4 2025 Earnings Call Transcript
Unknown2-25
The earnings call presents a mixed picture: strong financial metrics with improved gross margins and a share repurchase program, yet weak guidance for 2025 with declining revenues in key segments. The Q&A reveals some uncertainties in product launches and funding stabilization. While there are positive signs like potential growth in 2026 and successful market expansion, the lack of clear guidance and current revenue declines balance these out, leading to a neutral sentiment prediction.
OraSure Technologies, Inc. (OSUR) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call presents a mixed outlook. While revenue and margins are stable, significant challenges include declining international diagnostics revenue and economic uncertainties. The positive aspects include operational efficiencies, innovation investments, and a share repurchase program. The Q&A provides a strategic fit for acquisitions and improved gross margins, but risks like regulatory approvals and market conditions persist. Overall, the sentiment is balanced, suggesting a neutral stock price movement.
OraSure Technologies, Inc. (OSUR) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call presents a mixed picture: strong core revenue and gross margin improvements are positive, but significant challenges include revenue decline from a major customer, NIH funding cuts, and high operating losses. The Q&A reveals uncertainties in revenue guidance and manufacturing transition impacts. The share repurchase is a slight positive, but overall, the sentiment is neutral due to balanced positive and negative factors. The lack of clear guidance and uncertainties in key areas temper potential optimism.
OSUR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
